What happened

Shares of Seattle Genetics (NASDAQ:SGEN) are up 12% at 12:05 p.m. EDT after the biotech presented a pair of positive clinical trial results at the 2019 European Society for Medical Oncology (ESMO) Congress.

So what

In a phase 2 clinical trial testing Seattle Genetics' tucatinib with Roche's Herceptin in patients with a specific type of late-stage colorectal cancer, over half of the 23 patients responded to the therapy. The combination delayed the progression of the tumor and/or death by 8.1 months. Patients lived for a median of 18.7 months.

There wasn't a control arm to compare the data with, but these are heavily treated patients who have already failed two other approved treatments, so a 52.2% response rate is pretty impressive.

Doctor showing a report to a man in a hospital bed

Image source: Getty Images.

Seattle Genetics also presented initial data from a phase 1 clinical trial, dubbed EV-103, testing its enfortumab vedotin (EV) with Merck's (NYSE:MRK) Keytruda in patients with previously untreated, locally advanced, or metastatic urothelial cancer who can't take a chemotherapy called cisplatin. The response rate for the combination was 71% for the 45 patients, with 13% having a complete response and the other 58% having a partial response.

There wasn't a control arm to compare the data with in this study, either, but a phase 2 study that Merck used to get Keytruda approved for urothelial cancer patients who can't take cisplatin showed 29% of patients responded to the drug. Even in patients with high expression of PD-L1, the pathway that Keytruda targets, the response rate was only 47%, substantially below the 71% response rate for the combination.

Now what

Both drugs are already in late-stage testing -- EV is already under Food and Drug Administration review -- but the data at ESMO will help the biotech expand the potential market for both drugs.

EV is under FDA review for patients with late-stage urothelial cancer who have already received a PD-1/L1 inhibitor, such as Keytruda, so moving it into the first-line setting would greatly increase the number of urothelial cancer patients eligible to take EV.

Tucatinib is in a late-stage trial called Her2climb in patients with metastatic breast cancer, so the data in colorectal cancer offers a new opportunity to expand into an additional tumor type, while also giving investors additional confidence that Her2climb will be positive.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.